S&E Briefs: The Good and The Bad Of COVID-19 On Biotech's Top Line

 
• By Jessica Merrill

Regeneron's COVID-19 antibody cocktail helped drive 38% growth for the company, while Global Blood Therapeutics' Oxbryta continues to face headwinds and Horizon focuses on relaunches.

Thumbs up and down
Biopharma's S&E highs and lows • Source: Alamy

More from Earnings

More from Business